1例老年心房纤颤行导管消融术患者抗凝治疗分析及药学监护的报道

Abstract
Figure/Table
References (15)
Related Citation (15)

Download: PDF (0 KB) HTML (32 KB)
Export: BibTeX | EndNote (RIS)

Abstract In this paper, one elderly atrial fibrillation patient with anticoagulant therapy undergoing catheter ablation was given pharmacological monitoring and guidance from the causes of Warfarin international standardized ratio (INR)fluctuations, the perioperative period and the formulation of long-term anticoagulation programs, the conversion between traditional oral anticoagulants and new oral anticoagulants, and precautions for taking anticoagulants.Through active pharmacological monitoring and guidance by the clinical pharmacist, there were no thrombotic and hemorrhagic adverse events during catheter ablation, and the anticoagulation strategy was adjusted to a new oral anticoagulant: Dabigatran, to ensure sufficient anticoagulant efficacy and also reduce the risk of bleeding.The clinical pharmacist and the medical care providing proper pharmacological management of perioperative anticoagulation for such elderly patients,not only ensures the rationality of anticoagulation treatment, but also ensures the safety and continuity of anticoagulation.

Key words： Atrial fibrillation Anticoagulation Pharmaceutical monitoring New oral anticoagulant Perioperative period

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	HUANG Min-yan
	CHEN Xia

Cite this article:

HUANG Min-yan,CHEN Xia. Anticoagulant therapy analysis and pharmaceutical monitoring in an elderly patient with atrial fibrillation undergoing catheter ablation: a case report[J]. 中国当代医药, 2020, 27(12): 196-198转224.

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2020/V27/I12/196

[1]	Guo Y，Tian Y，Wang H，et al.Prevalence，incidence，and lifetime risk of atrial fibrillation in China：new insights into the global burden of atrial fibrillation[J].Chest，2015，147（1）：109-119.
[2]	颜建龙，赛音夫，LAM HOANG TRUC，等.新型口服抗凝药对我国非瓣膜性心房颤动患者治疗效果与安全性的Meta分析[J].中国全科医学，2017，20（11）：1341-1346.
[3]	Camm AJ，Lip GY，De Caterina R，et al.2012 focused update of the ESC Guidelines for the management of atrial fibrillation：an update of the 2010 ESC Guidelines for the management of atrial fibrillation.Developed with the special contribution of the European Heart Rhythm Association[J].Eur Heart J，2012，33（21）：2719-2747.
[4]	利伐沙班临床应用中国专家.利伐沙班临床应用中国专家建议—非瓣膜病心房颤动卒中预防分册[J].中华内科杂志，2013，52（10）：897-902.
[5]	程永梅，刘俊.基因多态性对华法林抗凝疗效影响的研究进展[J].临床合理用药杂志，2018，11（1A）：176-178.
[6]	杨尚珂，赵强.心房颤动射频消融围术期的抗凝治疗进展[J].医学综述，2018，24（5）：931-935.
[7]	Calkins H，Willems S，Gerstenfeld EP，et al.Uninterrupted Dabigatran versus Warfarin for ablation in atrial fibrillation[J].N Engl J Med，2017，377（5）：495-496.
[8]	Cappato R，Marchlinski FE，Hohnloser SH，et al.Uninterrupted rivaroxaban vs.uninterrupted vitamin K antagonists for catheter ablation in non-valvular atrial fibrillation[J].Eur Heart J，2015，36（28）：1805-1811.
[9]	刘启明.房颤消融术后抗凝药物停止时机[J].医学与哲学，2016，37（12B）：13-15.
[10]	张怡，龙萍，吕东莲.1例心房颤动伴短暂性脑缺血抗凝治疗的药学监护[J].医药导报，2016，38（8）：896-899.
[11]	任小婵，罗选娟，杨欢，等.新型口服抗凝药的临床应用研究进展[J].中华全科医学，2018，16（4）：615-619.
[12]	王婵娟，杨硕，张捷，等.达比加群服药患者出血风险的实验室检测[J].临床检验杂志，2017，35（12）：908-912.
[14]	Bauer KA.Pros and cons of new oral anticoagulants[J].Hematology Am Soc Hematol Educ Program，2013，2013：464-470.
[15]	华伟，金汉.老年心房颤动患者的抗凝管理[J].中华老年医学杂志，2017，36（3）：248-250.
[13]	January CT，Wann LS，Alpert JS，et al.2014AHA/ACC/HRS guideline for the management of patients with atrial fibrillation：A report of the American College of Cardiology/American Heart Assocation Task Force on Practice Guidelines and the Heart Rhythm Society[J].J Am Coll Cardiol，2014，64（21）：e1-e76.